The chief objectives are to reduce the patient’s symptom duration and severity, prevent both acute and delayed complications, and forestall an overspill of the infection to others.
This contagious respiratory disease results in upwards of 80,000 hospitalizations in the United States annually among children aged younger than 5 years, and infants are especially vulnerable.
Gene modulator therapies increase the life expectancy of patients with this disorder, which is caused by altered anion channel function in epithelial cells.
HEPLISAV-B™